Simultaneous targeting of estrogen receptor and HER2 in breast cancer (Q37782093)

23 August 2017

Simultaneous targeting of estrogen receptor and HER2 in breast cancer (English)

1 reference

23 August 2017

1 reference

1 reference

Hatem A Azim

1

1 reference

PubMed ID

20735311

23 August 2017

Martine J Piccart

series ordinal

2

1 reference

23 August 2017

1 August 2010

1 reference

Expert Review of Anticancer Therapy

23 August 2017

1 reference

23 August 2017

10

1 reference

23 August 2017

8

1 reference

23 August 2017

1255-1263

1 reference

Gene-expression signatures in breast cancer

23 August 2017

1 reference

Molecular portraits of human breast tumours

21 January 2018

1 reference

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

21 January 2018

1 reference

Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases

21 January 2018

1 reference

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer

21 January 2018

1 reference

Combining trastuzumab (Herceptin) with hormonal therapy in breast cancer: what can be expected and why?

21 January 2018

1 reference

PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer

21 January 2018

1 reference

The multiple roles of PTEN in tumor suppression

21 January 2018

1 reference

Targeting Her-2/neu in breast cancer: as easy as this!

21 January 2018

1 reference

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

21 January 2018

1 reference

Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.

21 January 2018

1 reference

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies

21 January 2018

1 reference

Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers

21 January 2018

1 reference

Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer

21 January 2018

1 reference

Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance

21 January 2018

1 reference

Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase

21 January 2018

1 reference

The SMRT corepressor is regulated by a MEK-1 kinase pathway: inhibition of corepressor function is associated with SMRT phosphorylation and nuclear export

21 January 2018

1 reference

AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor

21 January 2018

1 reference

Specific progesterone receptors in human breast cancer

21 January 2018

1 reference

Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women

21 January 2018

1 reference

Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity i

21 January 2018

1 reference

Fos and Jun inhibit estrogen-induced transcription of the human progesterone receptor gene through an activator protein-1 site

21 January 2018

1 reference

Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance

21 January 2018

1 reference

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer

21 January 2018

1 reference

Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole

21 January 2018

1 reference

A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer

21 January 2018

1 reference

Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group

21 January 2018

1 reference

Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer

21 January 2018

1 reference

Serum HER-2/neu and Response to the Aromatase Inhibitor Letrozole Versus Tamoxifen

21 January 2018

1 reference

Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status

21 January 2018

1 reference

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety upda

21 January 2018

1 reference

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

21 January 2018

1 reference

Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial

21 January 2018

1 reference

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer

21 January 2018

1 reference

Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial

21 January 2018

1 reference

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.

21 January 2018

1 reference

Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen

21 January 2018

1 reference

Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts

21 January 2018

1 reference

Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.

21 January 2018

1 reference

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

21 January 2018

1 reference

Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer

21 January 2018

1 reference

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.

21 January 2018

1 reference

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer.

21 January 2018

1 reference

Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells

21 January 2018

1 reference

Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in metastatic breast cancer.

21 January 2018

1 reference

Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatme

21 January 2018

1 reference

Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial

21 January 2018

1 reference

Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer.

21 January 2018

1 reference

Overcoming endocrine therapy resistance by signal transduction inhibition

21 January 2018

1 reference

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

21 January 2018

1 reference

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

Aromatase inhibitors and breast cancer

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.10.99

1 reference

23 August 2017

1 reference

PubMed ID

20735311